

# Breast Cancer Pathways: Advanced/Metastatic Disease

Patient Name: \_\_\_\_\_ Date of Birth: \_\_\_\_\_

Member Number: \_\_\_\_\_ Treatment Start Date: \_\_\_\_\_

Pathology: \_\_\_\_\_ Stage: \_\_\_\_\_

Line of Therapy: \_\_\_\_\_ ICD-10 Code: \_\_\_\_\_

Biomarkers/Characteristics: (Select all that apply)

Hormone Receptor (ER or PR): \_\_Negative \_\_Positive

OncotypeDx: \_\_Low \_\_Intermediate \_\_High \_\_Not Done/Reported

HER2 status: \_\_Negative \_\_Positive \_\_Equivocal

Include ovarian suppression (pre-menopause only): \_\_Yes \_\_No

## First Line of Therapy (1st Line) – Stage IV and Recurrent

- HER2 Positive
  - Capecitabine (Xeloda) and trastuzumab
  - Gemcitabine (Gemzar) and trastuzumab
  - Paclitaxel and trastuzumab
  - Pertuzumab (Perjeta), trastuzumab, and docetaxel (Taxotere)
  - Pertuzumab (Perjeta), trastuzumab, and paclitaxel
  - Vinorelbine (Navelbine) and trastuzumab

## Second or Third Line of Therapy (2<sup>nd</sup> or 3<sup>rd</sup> Line) – Stage IV and Recurrent

- HER2 Positive
  - Fam-trastuzumab deruxtecan-nxki (Enhertu) (2<sup>nd</sup> line only)
- HER2 Low
  - Fam-trastuzumab deruxtecan-nxki (Enhertu)

## First, Second, and Third Lines of Therapy (1<sup>st</sup>, 2<sup>nd</sup>, and 3<sup>rd</sup> Line) – Stage IV and Recurrent

- HER2 Negative and Hormone Receptor (ER or PR) Positive
  - Capecitabine (Xeloda)
  - Doxorubicin (Adriamycin)
  - Gemcitabine (Gemzar)
  - Paclitaxel
  - Vinorelbine (Navelbine)
- Triple Negative Breast Cancer (ER, PR, and HER2 negative)
  - Capecitabine (Xeloda)
  - Doxorubicin (Adriamycin)
  - Gemcitabine (Gemzar)
  - Paclitaxel
  - Vinorelbine (Navelbine)
  - Sacituzumab govitecan-hziy (Trodelvy) (third line only)

Note: Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars of reference products listed are considered “on pathway.” However, reimbursement for biosimilar products may be impacted by health plan specific formularies, medical policy and preferred product rules.



8600 West Bryn Mawr Avenue  
South Tower – Suite 800 Chicago, IL

Last review: 11/1/2022 | Effective date: 1/16/2023

© 2023 Carelon Medical Benefits Management

## First, Second, and Third Lines of Therapy (1<sup>st</sup>, 2<sup>nd</sup>, and 3<sup>rd</sup> Line) – Stage IV and Recurrent

- Triple Negative Breast Cancer (ER, PR, and HER2 negative), CPS ≥ 10
    - Pembrolizumab (Keytruda) and nab-paclitaxel (Abraxane)
    - Pembrolizumab (Keytruda) and paclitaxel
    - Pembrolizumab (Keytruda), gemcitabine (Gemzar), and carboplatin
- 

Note: Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars of reference products listed are considered “on pathway.” However, reimbursement for biosimilar products may be impacted by health plan specific formularies, medical policy and preferred product rules.



8600 West Bryn Mawr Avenue  
South Tower – Suite 800 Chicago, IL

Last review: 11/1/2022 | Effective date: 1/16/2023

© 2023 Carelon Medical Benefits Management